Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA:DHA Formulation
Ontario (ots/PRNewswire)
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced that it received a Notice of Allowance for U.S. Application Serial Number US2012/025014 from the United States Patent and Trademark Office (USPTO). The patent titled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics" covers Pivotal's unique formulation in conjunction with anti-obesity agents for the reduction of body weight in CVD patients and diabetics. This notice constitutes allowance of the patent and impending issuance.
"This Notice of Allowance is an important step in the process of broadening our intellectual property portfolio, further validates our unique 6:1 EPA:DHA formulation and when used in combination with anti-obesity drugs may play a positive role in obesity," said Dr. George Jackowski, Chairman and Chief Scientific Officer. "Obesity and diabetes are large markets, and this allowed patent may open the doors to potential partnerships with pharmaceutical companies that are currently working on treatments in these areas," added Dr. Jackowski.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN(R) is a prescription only Medical Food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN(R)is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN(R) is a patented product available for sale and distribution in Canada.
About VASCAZEN(R)
VASCAZEN(R) is currently available in the U.S. as a prescription-only Medical Food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN(R) is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN(R) has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. VASCAZEN(R)'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.
Disclosure Notice
The information contained in this document is as of January 29, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.
Company Contacts:
Rachelle MacSweeney President and Chief Operating Officer Phone: +1-905-856-9797 E-Mail: rmacsweeney@pivotaltherapeutics.us Kristine DiMatteo Communications and Public Relations Manager Phone: +1-905-856-9797 ext. 231 E-Mail: kdimatteo@pivotaltherapeutics.us